epcoritamab

Asset

Bispecific antibody targeting CD3 and CD20 to induce T-cell mediated lymphoma cell killing

Stage: Phase 3
Modality: Antibody
Target: Apoptosis; 1
Indication: 0
Trials: 1
Developer

Indications

1

Diffuse large B-cell lymphoma
Phase 3, globenewswire.com, 5 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners2
Evidence for its targets2
Competitors6
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source